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Appendix:
The aim of this appendix is to represent the process of data manipulation that has been implemented to obtain the cost parameters that we used in the probabilistic model. The purpose is thus to illustrate the deterministic data as selected from the literature review and their mean value in order to provide further insights in terms of a (deterministic) measure of the per capita costs incurred by schizophrenic patients in Italy. This was made to ensure the reproducibility of the model as it was before running the Montecarlo simulations. By doing so, an alternative stratification by drug category (FGA,FGA/SGA,SGA) was provided together with the weights used to calculate the average value used in the model. In table 1,2 we report the epidemiological and cost parameters. In table 3,4 we report the cost parameters with regard to polytherapy and monotherapy. Patients under other drugs (CNS) or those that were not treated are not reported as only one source from literature was considered for their estimation, thus no interval was built. Finally, in figure 1 we report the PRISMA as by our systematic review of the literature. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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